<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Selection of multiple myeloma therapy at first or second relapse</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Selection of multiple myeloma therapy at first or second relapse</h1>
<div class="graphic"><div class="figure"><div class="ttl">Selection of multiple myeloma therapy at first or second relapse</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">There is no single standard therapy for relapsed or refractory MM and practice varies widely; as such, we encourage eligible patients to participate in clinical trials. This algorithm illustrates our approach to selecting systemic therapy in most patients with first or second relapse. Other regimens are available and may be used by other experts. The choice for an individual must take into account expected toxicities, comorbidities, drug accessibility, and disease aggressiveness. In addition, all patients are assessed at the time of relapse to determine eligibility for autologous HCT.</div><div class="graphic_footnotes">MM: Multiple myeloma;
	DRd: Daratumumab, lenalidomide, and dexamethasone;
	KRd: Carfilzomib, lenalidomide, and dexamethasone; 
	IRd: Ixazomib, lenalidomide, and dexamethasone; 
	ERd: Elotuzumab, lenalidomide, dexamethasone;
	DKd: Daratumumab, carfilzomib, and dexamethasone; 
	IsaKd: Isatuximab, carfilzomib, and dexamethasone;
	DPd: Daratumumab, pomalidomide, and dexamethasone; 
	IsaPd: Isatuximab, pomalidomide, and dexamethasone; 
	KPd: Carfilzomib, pomalidomide, and dexamethasone; 
	VPd: Bortezomib, pomalidomide, and dexamethasone; 
	VCd: Bortezomib, cyclophosphamide, and dexamethasone; 
	SVd: Selinexor, bortezomib, and dexamethasone; 
	DVd: Daratumumab, bortezomib, dexamethasone;
	HCT: Hematopoietic cell transplantation.<br/>
	
	* We use the following cutoffs to define refractory and not refractory MM to guide therapy: 
	<ul>
<li>Refractory: progression within 60 days of exposure to an agent at standard doses</li>
<li>Sensitive: progression &gt;60 days from last exposure or progression on minimal therapy (eg, lenalidomide 10 mg or monthly daratumumab)</li>
</ul></div><div id="graphicVersion">Graphic 134483 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
